Ionis Pharmaceuticals (MIL:1IONS) Cyclically Adjusted FCF per Share: €-0.29 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1IONS Ionis Pharmaceuticals Inc MIL:1IONS
46 GF Score
Price €40.52
GF Value €43.33
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Cyclically Adjusted FCF per Share?

Ionis Pharmaceuticals MIL:1IONS -14.80% 46 Cyclically Adjusted FCF per Share is €-0.29 as of Jun. 2026. GuruFocus rates MIL:1IONS with a GF Score™ of 46/100 and a GF Value™ of €43.33 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was €2.831. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.29 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Ionis Pharmaceuticals was 84.20% per year. The lowest was -17.40% per year. And the median was 9.40% per year.

As of today (2026-09-17), Ionis Pharmaceuticals's current stock price is €40.52. Ionis Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-0.29. Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Ionis Pharmaceuticals was 5829.00. The lowest was 39.84. And the median was 113.72.


Ionis Pharmaceuticals  (MIL:1IONS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Ionis Pharmaceuticals was 5829.00. The lowest was 39.84. And the median was 113.72.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.55 0.30 -0.03 -0.22

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -0.22 -0.26 -0.61 -0.29

MIL:1IONS vs APGE, CYTK, KRYS: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


MIL:1IONS
46GF Score
Ionis Pharmaceuticals Inc MIL:1IONS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.831/333.9520*333.9520
=2.831

Current CPI (Jun. 2026) = 333.9520.

Ionis Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.144 241.428 0.199
201612 -0.247 241.432 -0.342
201703 0.889 243.801 1.218
201706 -0.061 244.955 -0.083
201709 0.010 246.819 0.014
201712 0.088 246.524 0.119
201803 0.065 249.554 0.087
201806 3.213 251.989 4.258
201809 -0.113 252.439 -0.149
201812 0.715 251.233 0.950
201903 0.644 254.202 0.846
201906 -0.199 256.143 -0.259
201909 -0.187 256.759 -0.243
201912 1.621 256.974 2.107
202003 -0.109 258.115 -0.141
202006 -0.347 257.797 -0.450
202009 -0.109 260.280 -0.140
202012 0.568 260.474 0.728
202103 -0.333 264.877 -0.420
202106 -0.395 271.696 -0.486
202109 -0.370 274.310 -0.450
202112 1.070 278.802 1.282
202203 -0.216 287.504 -0.251
202206 -0.153 296.311 -0.172
202209 -0.231 296.808 -0.260
202212 -1.404 296.797 -1.580
202303 -0.943 301.836 -1.043
202306 -0.689 305.109 -0.754
202309 -0.714 307.789 -0.775
202312 0.190 306.746 0.207
202403 -0.978 312.332 -1.046
202406 -0.811 314.175 -0.862
202409 -0.725 315.301 -0.768
202412 -0.910 315.605 -0.963
202503 -0.978 319.799 -1.021
202506 0.734 322.561 0.760
202509 -0.728 324.800 -0.749
202512 -0.847 324.054 -0.873
202603 -4.223 330.213 -4.271
202606 2.831 333.952 2.831

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.29 mean?
Ionis Pharmaceuticals (MIL:1IONS) has a Cyclically Adjusted FCF per Share of €-0.29 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Ionis Pharmaceuticals' current Cyclically Adjusted FCF per Share is €-0.29. Overall, Ionis Pharmaceuticals has a GF Score™ of 46/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Cyclically Adjusted FCF per Share compare to APGE and CYTK?
Ionis Pharmaceuticals' Cyclically Adjusted FCF per Share of €-0.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Cyclically Adjusted FCF per Share is €-0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (MIL:1IONS) is currently considered Fairly Valued. The stock's GF Value™ is €43.33, compared to a current price of €40.52 — trading 6.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.29. Ionis Pharmaceuticals' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Ionis Pharmaceuticals (MIL:1IONS), the current Cyclically Adjusted FCF per Share is €-0.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MIL:1IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be undervalued. The current stock price of €40.52 is trading 6.5% below its estimated GF Value™ of €43.33. GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.

Key valuation signals for MIL:1IONS:

  • Cyclically Adjusted FCF per Share: €-0.29
  • GF Value™: €43.33 vs. price of €40.52 (6.5% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the MIL:1IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA0JDI:UKISI:Germany
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
46GF Score

Get the complete analysis for MIL:1IONS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.52
Price
€43.33
GF Value